Storia in 2 fonti

Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sanofi (NASDAQ:SNY)

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 mesi fa

Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sanofi (NASDAQ:SNY)

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.

originale

endpoints.news2 mesi fa

Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies

Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US.

Leggi questa versione → originale

Timeline cronologica

martedì 30 giugno 2026·endpoints.news
Sanofi’s Pompe disease treatment successor passes Phase 3 test in babies
Sanofi said its enzyme replacement therapy succeeded in a registrational trial in a severe form of Pompe disease, paving the way for a key label expansion in the US.
martedì 30 giugno 2026·benzinga.com
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sanofi (NASDAQ:SNY)
Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.